Clinical Trial Update: Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating inetetamab in combination with pyrotinib for HER2-mutant or amplified advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Inetetamab (inetetamab)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN